Clinical trials: Mpox
Monkeypox
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
- Trial name
- M-BOOST-FR (NCT06885853)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mpox (Monkeypox), Smallpox
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
- Conditions
- Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection
- Trial name
- NCT07379580
- Testing
- BNT166a
- Where
- 6 sites in Democratic Republic of the Congo, South Africa
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Monkeypox (Mpox)
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).
- Trial name
- NCT07253675
- Testing
- MVA-SIBP low dose, MVA-SIBP high dose, MVA-BN
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Monkeypox (Mpox)
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).
- Trial name
- NCT06549530
- Testing
- MVA-BN
- Where
- 3 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Monkeypox, Mpox (Monkeypox)
Ocular Complications of Mpox in the Democratic Republic Congo
This is an observational study in which patients diagnosed with mpox will be enrolled, will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox.
- Trial name
- MPOX-EYE (NCT06579885)
- Where
- Democratic Republic of the Congo
- Volunteers
- 320 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkeypox
Mpox Prospective Observational Cohort Study
The goal of this multicentre prospective observational cohort study is to shed light on the following unknowns: 1. The clinical manifestations of Mpox infection since the 2022 outbreak in Canada. 2.
- Trial name
- MPOCS (NCT06291259)
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Unity Health Toronto
Mpox
Break-through Infection Following Mpox vaccinatIon
The purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.
- Trial name
- REMAIN (NCT05522296)
- Testing
- Mpox Vaccine
- Where
- 6 sites in Chile, Panama and 2 more
- Volunteers
- 3,125 people, healthy volunteers welcome
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Mpox (Monkeypox)
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
The goal of this study is to evaluate the effectiveness of smallpox vaccination administered before the global eradication of smallpox against currently circulating mpox in the Democratic Republic of the Congo.
- Trial name
- NCT06984705
- Where
- Democratic Republic of the Congo
- Volunteers
- 144 people
- Sponsor
- Osaka Metropolitan University
Mpox (Monkeypox)
An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.
- Trial name
- Mbote-HIVAX (NCT06839989)
- Testing
- Mpox vaccination with MVA-BN
- Where
- Democratic Republic of the Congo
- Volunteers
- 600 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkeypox Virus Infection
A One Health Study of Monkeypox Human Infection
This multidisciplinary project aim to understand the epidemiology of the monkeypox in Central African Republic through the identification of the animal reservoir, the clinical and epidemiological description of the human…
- Trial name
- AFRIPOX (NCT05058898)
- Testing
- blood samples, Scabs and pus samples
- Where
- Central African Republic
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Monkeypox
Tecovirimat for Treatment of Monkeypox Virus
The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC).
- Trial name
- NCT05559099
- Testing
- Tecovirimat Oral Capsule
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 597 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mpox (Monkeypox)
Looking for Asymptomatic Mpox in a Population at High Risk
Mpox is caused by a virus that can be spread through touching the affected skin of someone who has the infection, touching sheets or clothes that has been used by someone with the infection, or breathing in particles of virus…
- Trial name
- LAMP (NCT06353737)
- Where
- Canada
- Volunteers
- 450 people
- Sponsor
- Unity Health Toronto
Mpox (Monkeypox), Mpox
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
This is a health facility-based prospective test-negative (TND) case-control study to evaluate vaccine effectiveness and active safety monitoring (cohort event monitoring), and passive surveillance for evaluation of the safety of…
- Trial name
- MPX-001 (NCT07093489)
- Testing
- LC16m8
- Where
- Democratic Republic of the Congo
- Volunteers
- 11,990 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Monkeypox (Mpox)
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)
The goal of this observational study is to better understand the dominant modes of transmission to estimate the extent of transmission among contacts by determining the secondary infection rate for human-to-human transmission at…
- Trial name
- NCT07067723
- Where
- Democratic Republic of the Congo
- Volunteers
- 122 people
- Sponsor
- Osaka Metropolitan University
Monkeypox (Mpox)
Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)
This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it.
- Trial name
- MBOTE-EPIC (NCT06840860)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 1,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Mpox (Monkeypox), Monkeypox
Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea
This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV)…
- Trial name
- MOVIE-TRACE-WA (NCT07534267)
- Where
- Guinea
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Mpox (Monkeypox), Vaccination
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic…
- Conditions
- Mpox (Monkeypox), Vaccination, Immunogenicity, Safety
- Trial name
- PregInPoxVac (NCT06844487)
- Testing
- MVA-BN standard regimen, MVA-BN half-dose regimen
- Where
- Democratic Republic of the Congo
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Monkeypox, Mpox
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
The overall purpose of this study is to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older).
- Trial name
- UNITY (NCT05597735)
- Testing
- Tecovirimat
- Where
- 12 sites in Argentina, Brazil and 1 more
- Volunteers
- 480 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Monkeypox
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
This was a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox…
- Trial name
- NCT05988203
- Testing
- BNT166a
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Mpox (Monkeypox)
Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort
Primary objective The overall objective is to assess the long-term amplitude and durability of the immune responses after mpox virus (MPXV) infection.
- Trial name
- POXAIM (NCT07592429)
- Testing
- blood sampling
- Volunteers
- 60 people
- Sponsor
- ANRS, Emerging Infectious Diseases